UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014122
Receipt number R000016422
Scientific Title Investigation of appetite suppressant properties associated with Coleus forskohlii in overweight and obese individuals
Date of disclosure of the study information 2014/08/11
Last modified on 2014/08/11 15:54:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of appetite suppressant properties associated with Coleus forskohlii in overweight and obese individuals

Acronym

The effect of Coleus forskohlii extract on the risk factors of metabolic syndrome

Scientific Title

Investigation of appetite suppressant properties associated with Coleus forskohlii in overweight and obese individuals

Scientific Title:Acronym

The effect of Coleus forskohlii extract on the risk factors of metabolic syndrome

Region

Australia


Condition

Condition

Metabolic syndrome
Obesity

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the appetite suppressant properties of Coleus forskohlii extract after three months administration in overweight and obese individuals.
To assess the effect of Coleus forskohlii on central obesity and risk factors of metabolic syndrome in overweight and obese individuals.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in appetite will be assessed using visual analogue scale.
changes in blood hormone levels will be analyzed using commercial kits.

Key secondary outcomes

Reduction in central obesity - waist circumference will be measured on fortnight basis.
Changes in blood lipids will be analysed using commercial kits.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Administration of Coleus forskohlii extract

Interventions/Control_2

Administration of Placebo control (microcrystalline cellulose)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

Overweight or obese (BMI >25).
Waist circumference of >94 cm (male) and >80 cm (female).

Key exclusion criteria

Cigarette smoker.
Patient having any type of heart, liver and kidney diseases.
Pregnancy and lactating women.
Any medication for hypertension, type I diabetes and weight loss.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Dr. Xiao Su

Organization

Victoria University

Division name

College of Health and Biomedicine

Zip code


Address

St. Albans, Victoria, Austalia 14428

TEL

+61399192211

Email

xiao.su@vu.edu.au


Public contact

Name of contact person

1st name
Middle name
Last name Dr. Xiao Su

Organization

Victoria University

Division name

College of Health and Biomedicine

Zip code


Address

St. Albans, Victoria, Australia 14428

TEL

+61399192211

Homepage URL


Email

xiao.su@vu.edu.au


Sponsor or person

Institute

Victoria University

Institute

Department

Personal name



Funding Source

Organization

Victoria University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Australia


Other related organizations

Co-sponsor

Olive Lifesciences Pvt Ltd

Name of secondary funder(s)

Bio Actives Japan Corporation


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

ACTRN12614000305628

Org. issuing International ID_1

Australia New Zealand Clinical Trials Registry

Study ID_2

NCT02143349

Org. issuing International ID_2

ClinicalTrials.gov

IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 08 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 01 Month 20 Day

Date of IRB


Anticipated trial start date

2014 Year 04 Month 18 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 05 Month 30 Day

Last modified on

2014 Year 08 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016422


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name